📢#CTAD2025 is just two weeks away!
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
November 20, 2025 at 8:15 PM
📢#CTAD2025 is just two weeks away!
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
As we gear up to connect with leaders and researchers advancing Alzheimer’s disease diagnosis and research, we’re excited to launch our redesigned web experience – live today
🔗Explore now: www.alzpath.bio
Attending CTAD? Let’s connect: inquiry@alzpath.bio
How reliable are blood-based pTau217 tests compared to PET or CSF?
Studies show blood tests powered by the ALZpath #pTau217 antibody perform comparably to CSF testsfor detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis.
🔗Learn more: alzpath.bio/faqs
Studies show blood tests powered by the ALZpath #pTau217 antibody perform comparably to CSF testsfor detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis.
🔗Learn more: alzpath.bio/faqs
November 12, 2025 at 8:24 PM
How reliable are blood-based pTau217 tests compared to PET or CSF?
Studies show blood tests powered by the ALZpath #pTau217 antibody perform comparably to CSF testsfor detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis.
🔗Learn more: alzpath.bio/faqs
Studies show blood tests powered by the ALZpath #pTau217 antibody perform comparably to CSF testsfor detecting Alzheimer’s disease - a major step toward earlier, more accessible diagnosis.
🔗Learn more: alzpath.bio/faqs
We’re headed to #CTAD2025 in San Diego!
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
November 4, 2025 at 2:53 AM
We’re headed to #CTAD2025 in San Diego!
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
ALZpath will join global leaders in Alzheimer’s disease research and diagnostics to discuss advances in #pTau217 and blood-based biomarkers.
Attending? Let’s connect — reach out at inquiry@alzpath.bio to schedule a meeting.
#AlzheimersDisease #Research
💜 Yesterday was #WorldAlzheimersDay, honoring the millions living with Alzheimer’s disease and the families who support them.
At ALZpath, we’re committed to earlier, accessible blood-based diagnosis with #pTau217— because knowing sooner changes everything.
🔗Learn more at: www.alzpath.bio
At ALZpath, we’re committed to earlier, accessible blood-based diagnosis with #pTau217— because knowing sooner changes everything.
🔗Learn more at: www.alzpath.bio
September 22, 2025 at 6:47 PM
💜 Yesterday was #WorldAlzheimersDay, honoring the millions living with Alzheimer’s disease and the families who support them.
At ALZpath, we’re committed to earlier, accessible blood-based diagnosis with #pTau217— because knowing sooner changes everything.
🔗Learn more at: www.alzpath.bio
At ALZpath, we’re committed to earlier, accessible blood-based diagnosis with #pTau217— because knowing sooner changes everything.
🔗Learn more at: www.alzpath.bio
In a new executive interview with Drug Development & Delivery, our Chief Business Officer, Jacob Hunter shares how ALZpath’s #pTau217 antibody is enabling earlier, scalable detection of #AlzheimersDisease.
🔗Learn more in the full interview: drug-dev.com/executive-in...
#Antibody #ALZpath
🔗Learn more in the full interview: drug-dev.com/executive-in...
#Antibody #ALZpath
September 11, 2025 at 5:36 PM
In a new executive interview with Drug Development & Delivery, our Chief Business Officer, Jacob Hunter shares how ALZpath’s #pTau217 antibody is enabling earlier, scalable detection of #AlzheimersDisease.
🔗Learn more in the full interview: drug-dev.com/executive-in...
#Antibody #ALZpath
🔗Learn more in the full interview: drug-dev.com/executive-in...
#Antibody #ALZpath
September is #WorldAlzheimersMonth, a global call to raise awareness and take action.
Alzheimer’s disease, the leading cause of Dementia, too often goes undetected and leaves millions without answers.
At ALZpath, we’re working to change that. Learn more at alzpath.bio.
#AskAboutAlzheimers
Alzheimer’s disease, the leading cause of Dementia, too often goes undetected and leaves millions without answers.
At ALZpath, we’re working to change that. Learn more at alzpath.bio.
#AskAboutAlzheimers
September 9, 2025 at 6:48 PM
September is #WorldAlzheimersMonth, a global call to raise awareness and take action.
Alzheimer’s disease, the leading cause of Dementia, too often goes undetected and leaves millions without answers.
At ALZpath, we’re working to change that. Learn more at alzpath.bio.
#AskAboutAlzheimers
Alzheimer’s disease, the leading cause of Dementia, too often goes undetected and leaves millions without answers.
At ALZpath, we’re working to change that. Learn more at alzpath.bio.
#AskAboutAlzheimers
What a week at #AAIC2025 🧠
ALZpath was proud to connect with global leaders in Alzheimer’s disease care and our Advisory Board.
@alzassociation.bsky.social released new Blood-Based Biomarker Guidelines—congrats to Dr. Henrik Zetterberg, our Distinguished Scientific Advisor, for his contribution.
ALZpath was proud to connect with global leaders in Alzheimer’s disease care and our Advisory Board.
@alzassociation.bsky.social released new Blood-Based Biomarker Guidelines—congrats to Dr. Henrik Zetterberg, our Distinguished Scientific Advisor, for his contribution.
August 6, 2025 at 4:58 PM
What a week at #AAIC2025 🧠
ALZpath was proud to connect with global leaders in Alzheimer’s disease care and our Advisory Board.
@alzassociation.bsky.social released new Blood-Based Biomarker Guidelines—congrats to Dr. Henrik Zetterberg, our Distinguished Scientific Advisor, for his contribution.
ALZpath was proud to connect with global leaders in Alzheimer’s disease care and our Advisory Board.
@alzassociation.bsky.social released new Blood-Based Biomarker Guidelines—congrats to Dr. Henrik Zetterberg, our Distinguished Scientific Advisor, for his contribution.
ALZpath is headed to Toronto for #AAIC25!
If you’re attending and want to discuss pTau217 testing or Alzheimer’s diagnostics, we’d love to connect.
Email jacob@alzpath.bio to set up a meeting.
#AlzheimersDisease #AAIC25 #pTau217 #Diagnostics #ALZpath
If you’re attending and want to discuss pTau217 testing or Alzheimer’s diagnostics, we’d love to connect.
Email jacob@alzpath.bio to set up a meeting.
#AlzheimersDisease #AAIC25 #pTau217 #Diagnostics #ALZpath
June 27, 2025 at 4:28 PM
ALZpath is headed to Toronto for #AAIC25!
If you’re attending and want to discuss pTau217 testing or Alzheimer’s diagnostics, we’d love to connect.
Email jacob@alzpath.bio to set up a meeting.
#AlzheimersDisease #AAIC25 #pTau217 #Diagnostics #ALZpath
If you’re attending and want to discuss pTau217 testing or Alzheimer’s diagnostics, we’d love to connect.
Email jacob@alzpath.bio to set up a meeting.
#AlzheimersDisease #AAIC25 #pTau217 #Diagnostics #ALZpath